928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

S-B Kim,T.M Kim,S Shin,S Seo,M-J Ahn,S Lee,Y.S Chae,L.C Park,E Lim,B Keam,K Park,S-B Hong

doi:10.1016/j.annonc.2020.08.1043

928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

S-B Kim, T.M Kim + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1043

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 2	License type: publisher-specific-oa

Affiliation: Asan Medical Center, Seoul National University Hospital, Kosin University Gospel Hospital, Samsung Medical Center, Sungkyunkwan University

#anti-ErbB3 Monoclonal Antibody #Head And Neck Squamous Cell Carcinoma + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Full Text